Understand how semaglutide, the active ingredient in Ozempic®, influences blood glucose regulation, appetite and body weight. Explore the clinical evidence, safety considerations and medical factors that should be reviewed before using GLP-1 prescription medication.
After vitamin C (ascorbic acid) is metabolised in the body, a proportion can be converted into oxalate. Because calcium oxalate is a major component of many common kidney stones, the relationship between vitamin C intake and kidney stone risk has long been debated.
This early review examined the available evidence from vitamin C absorption, renal handling, oxalate metabolism, urinary oxalate measurement, and population studies to assess whether higher vitamin C intake was associated with calcium oxalate kidney stones.
Vitamin C can be metabolised in the body to form oxalate, and urinary oxalate is an important contributor to the formation of calcium oxalate kidney stones.
This raises a practical clinical question: does higher vitamin C intake increase kidney stone risk? This large prospective study followed women over many years and provides population-level risk information that differs substantially from individual case reports.
After high-dose intravenous vitamin C is metabolised in the body, a proportion can be converted into oxalate. When oxalate production increases and the kidneys are unable to eliminate it effectively, calcium oxalate crystals may form and deposit within the renal tubules, contributing to kidney injury.
Cases such as this do not mean that high-dose intravenous vitamin C inevitably causes renal injury. However, they provide an important safety signal regarding the relationship between oxalate metabolism, renal excretory capacity, and individual risk factors.
After vitamin C (ascorbic acid) is metabolised in the body, a proportion can be converted into oxalate, which is then primarily eliminated through the kidneys.
When vitamin C exposure is extremely high and renal excretory capacity is simultaneously reduced, the balance between oxalate production and elimination may be disrupted, increasing the risk of calcium oxalate crystal deposition and acute kidney injury.
After vitamin C (ascorbic acid) is metabolised in the body, a proportion can be converted into oxalate, which is then primarily eliminated through the kidneys.
In certain high-risk individuals, a substantial increase in oxalate burden may contribute to calcium oxalate crystal formation and deposition within the renal tubules. Renal function and previous kidney disease are therefore important safety considerations when high-dose intravenous vitamin C is being considered.
Continuous High-Dose Intravenous Vitamin C: An Early Safety Study in Patients with Advanced Cancer High-dose intravenous vitamin C (intravenous ascorbate) differs from routine oral vitamin
One important direction in research on high-dose intravenous vitamin C (intravenous ascorbate) is to examine whether it can be used alongside standard chemotherapy while maintaining an acceptable safety profile and potentially reducing some chemotherapy-related adverse effects.
In ovarian cancer research, investigators conducted laboratory, animal, and human clinical studies. For patients, one of the most relevant components was a small randomised clinical trial evaluating the safety and early clinical findings of adding intravenous vitamin C to carboplatin and paclitaxel.
An important question in research on high-dose intravenous vitamin C (intravenous ascorbic acid) is whether pharmacological concentrations can be achieved safely in humans, and how blood concentration, half-life, and tolerability change across different dose levels.
This Phase I study focused on patients with advanced solid tumours who had limited response to standard medical options, evaluating high-dose intravenous ascorbic acid as a single intervention with particular attention to safety, tolerability, and pharmacokinetics.
One important direction in research on high-dose intravenous vitamin C (intravenous ascorbate) has been to combine it with established cancer medicines and assess whether pharmacological plasma concentrations can be achieved while maintaining an acceptable safety profile.
In patients with pancreatic cancer, the PACMAN Phase I trial further evaluated the safety, tolerability, and early clinical observations associated with pharmacological ascorbate given alongside gemcitabine.